Sanofi-Regeneron’s Amgen Drug Rival Cuts Cholesterol

Sanofi and Regeneron Pharmaceuticals Inc.’s cholesterol drug cut levels of the heart disease-causing fat in four studies, and there are early indications it may prevent death and heart attack.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.